Yoshiki Akatsuka

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Dominant T cell receptor clonotypes in adrenocorticotropic hormone-secreting pituitary carcinoma are the highest-frequency clones among CD4+ and CD8+ cells in peripheral blood during effective anti-PD-1 therapy.

Dominant T cell receptor clonotypes in adrenocorticotropic hormone-secreting pituitary carcinoma are the highest-frequency clones among CD4+ and CD8+ cells in peripheral blood during effective anti-PD-1 therapy.

Journal: Frontiers in immunology

Published: May 08, 2026

Current status and challenges of TCR-T cell therapy for AML/MDS.

Current status and challenges of TCR-T cell therapy for AML/MDS.

Journal: International journal of hematology

Published: January 07, 2026

Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-Related Haplotypes.

Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-Related Haplotypes.

Journal: Cancer immunology research

Published: June 04, 2025

Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related Haplotypes.

Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related Haplotypes.

Journal: Cancer immunology research

Published: June 04, 2025

Bilateral reversible optic neuropathy as the first sign of Waldenström macroglobulinema.

Bilateral reversible optic neuropathy as the first sign of Waldenström macroglobulinema.

Journal: GMS ophthalmology cases

Published: July 12, 2024

Hematological immune-related adverse events of immune checkpoint inhibitors and their management

Hematological immune-related adverse events of immune checkpoint inhibitors and their management

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: September 06, 2023

Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.

Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.

Journal: International journal of hematology

Published: April 27, 2023

T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.

T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.

Journal: Nagoya journal of medical science

Published: July 13, 2022

CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma.

CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma.

Journal: Blood advances

Published: October 05, 2021

A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients.

A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients.

Journal: International journal of hematology

Published: June 26, 2020

TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.

TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.

Journal: Frontiers in immunology

Published: October 23, 2019

Progress in immune checkpoint inhibitor therapies

Progress in immune checkpoint inhibitor therapies

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 11, 2019

Showing 1-12 of 48

Last Updated: 09/26/2026